Top Markets
Coin of the day
Hansa Biopharma AB (publ) Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ)

HNSA
Rank in Stocks #13534
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing... Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain BarrΓ© syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
Share Price
$4.83
Market Cap
$481.23M
Change (1 day)
-3.01%
Change (1 year)
41.08%
Country
SE
Trade Hansa Biopharma AB (publ) (HNSA)

Category

Stock price history for Hansa Biopharma AB (publ) (HNSA)
Highest end of day price: $4.66 on 2026-08-01

Lowest end of day price: $1.23 on 2007-10-01
Stock price history of Hansa Biopharma AB (publ) from 2007 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) 3.21%
2025 18.06%
2024 24.12%
2023 -52.92%
2022 -47.02%
2021 -65.69%
2020 170.40%
2019 -67.23%
2018 9.70%
2017 122.57%
2016 324.99%
2015 -11.09%
2014 181.45%
2013 131.04%
2012 -16.18%
2011 22.26%
2010 -23.87%
2009 62.04%
2008 -57.53%
2007 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$541.91 38.59%
US
$1.02K 43.54%
NL
$121.01 -13.08%
AU
$142.73 492.49%
US
$749.90 5.87%
CH